I was doing some DD on this stock on the basis today's fall may be overdone.
However, I noticed on Clinicaltrials.gov that their Azixa Phase II trial on Glioblastoma Multiforme (brain cancer) was marked down as suspended last Thursday, 19 August. The trial's Identifier is NCT00892931 if you wish to verify this.
Oddly, neither Epicept or their partner, Myrexis, have made any comment on this development.
To be fair, until the background to the suspension is explained, it's not fully clear what the implications are. However, it has to be marked down as a negative development as of right now. It never rains but it pours ...